Treatment of premenstrual dysphoric disorder with the GABA A receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial

• Published in: Psychoneuroendocrinology Vol. 80; pp. 46 - 55
• Main Authors: Bixo, Marie, Ekberg, Karin, Poromaa, Inger Sundström, Hirschberg, Angelica Lindén, Jonasson, Aino Fianu, Andréen, Lotta, Timby, Erika, Wulff, Marianne, Ehrenborg, Agneta, Bäckström, Torbjörn
• Format: Journal Article
• Language: English
• Published: England 01.06.2017
• Subjects: Adult; Affect - physiology; Allopregnanolone; Anger; Anxiety; Contraceptives, Oral - pharmacology; Depression; Double-Blind Method; Female; Follicular Phase; GABA; GABA-A Receptor Antagonists - pharmacology; Humans; Isoallopregnanolone; Luteal Phase - drug effects; Menstrual Cycle; Middle Aged; Pregnanolone - pharmacology; Pregnanolone - therapeutic use; Premenstrual dysphoric disorder; Premenstrual Dysphoric Disorder - drug therapy; Premenstrual Syndrome; Progesterone - pharmacology; Randomized controlled trial; Randomized ntrolled trial; Receptors, GABA-A - drug effects; Receptors, GABA-A - metabolism; Serotonin Uptake Inhibitors - pharmacology; GABA; Isoallopregnanolone; Premenstrual dysphoric disorder; Randomized controlled trial; Allopregnanolone

Allopregnanolone is a metabolite from progesterone and a positive modulator of the GABA receptor. This endogenous steroid may induce negative mood in sensitive women when present in serum levels comparable to the premenstrual phase. Its endogenous isomer, isoallopregnanolone, has been shown to antag...